Dr. Reddy's Laboratories Ltd. closed 7.02% short of its 52-week high of 1,420.20 rupees, which the company achieved on August ...

HSBC upgraded Dr. Reddy’s Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from ...

Dr. Reddy's Labs ADR saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 0% to 16%.

Fintel reports that on June 5, 2025, HSBC upgraded their outlook for Dr. Reddy's Laboratories Limited - Depositary Receipt () ...

Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of ...

Dr. Crystal Truong and Dr. Vish Reddy opened the doors to Apex Eye in Frisco with a clear mission to create an ophthalmology ...

LIC’s shareholding in Dr. Reddy’s Laboratories rose from 5.6% at the end of September 2024 to 6.5% by December 2024, and ...

Discover the Dr Reddys Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Hyderabad-based Dr. Reddy’s Laboratories Ltd, on Thursday ...

Dr. Reddy's Laboratories Ltd. Sponsored ADR (RDY) is currently at $15.62, up $0.88 or 5.93% --Would be highest close since Jan. 8, 2025, when it closed at $15.81 --On pace for largest percent increase ...

Ontario, Calif.-based Prime Healthcare realigned services at Illinois hospitals it recently acquired from St. Louis-based Ascension, citing unsustainable financial losses and low patient volumes that ...